Success Metrics

Completion Rate

0%(0/1)

Active Trials

2(50%)

Terminated

1(25%)

Phase Distribution

Ph phase_1

75%

Ph phase_2

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

3(75.0%)

Phase 2Efficacy & side effects

1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Terminated(1)

Detailed Status

Recruiting2

Terminated1

Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

0.0%

Most Advanced

Phase 2

Trials by Phase

Phase 13 (75.0%)

Phase 21 (25.0%)

Trials by Status

terminated125%

not_yet_recruiting125%

recruiting250%

Recent Activity

2 active trials

Showing 4 of 4

terminatedphase_1

Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1

NCT06714591

recruitingphase_2

A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia

NCT07255872

not_yet_recruitingphase_1

A Study of BL-M11D1 in Patients With Relapsed/Refractory Myelodysplastic Syndromes

NCT07591168

recruitingphase_1

A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT05924750

Clinical Trials (4)

Showing 4 of 4 trials

NCT06714591Phase 1

Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1

Terminated

NCT07255872Phase 2

A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia

Recruiting

NCT07591168Phase 1

A Study of BL-M11D1 in Patients With Relapsed/Refractory Myelodysplastic Syndromes

Not Yet Recruiting

NCT05924750Phase 1

A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Recruiting

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4